Aerie Pharmaceuticals CEO Vicente Anido's 2020 pay falls 35% to $3.6M
Aerie Pharmaceuticals reports 2020 executive compensation
By ExecPay News
Published: April 27, 2021
Aerie Pharmaceuticals reported fiscal year 2020 executive compensation information on April 27, 2021.
In 2020, six executives at Aerie Pharmaceuticals received on average a compensation package of $1.7M, a 41% decrease compared to previous year.
Average pay of disclosed executives at Aerie Pharmaceuticals
Vicente Anido, Jr., Chief Executive Officer, received $3.6M in total, which decreased by 35% compared to 2019. 47% of Anido's compensation, or $1.7M, was in option awards. Anido also received $521K in non-equity incentive plan, $796K in salary, as well as $593K in stock awards.
Thomas A. Mitro, Chief Operating Officer, received a compensation package of $1.9M, which decreased by 32% compared to previous year. 45% of the compensation package, or $855K, was in option awards.
Richard J. Rubino, Chief Financial Officer, earned $1.7M in 2020, a 32% decrease compared to previous year.
Casey C. Kopczynski, Chief Scientific Officer, received $1.5M in 2020, which decreases by 24% compared to 2019.
John W. LaRocca, General Counsel, earned $945K in 2020, a 63% decrease compared to previous year.
David A. Hollander, Chief Research and Development Officer, received $649K in 2020, which decreases by 69% compared to 2019.
Related executives
Vicente Anido
Aerie Pharmaceuticals
Chief Executive Officer
Richard Rubino
Aerie Pharmaceuticals
Chief Financial Officer
Thomas Mitro
Aerie Pharmaceuticals
Chief Operating Officer
Casey Kopczynski
Aerie Pharmaceuticals
Chief Innovation Officer, Head of Research and External Innovation
John LaRocca
Aerie Pharmaceuticals
General Counsel
David Hollander
Aerie Pharmaceuticals
Chief Research and Development Officer
You may also like
Source: SEC filing on April 27, 2021.